Furthermore, closed-loop insulin administration devices (artificial pancreas) have shown a 27% decrease in hypoglycemia in individuals with type 1 diabetes [3]
For a long time, scientists believe that chronic neuroinflammation is crucial in cognitive impairment, and that GLP-1RAs protect synaptic and learning functions from neuroinflammation (119, 120)
It's why prescription GLP-1 medications like Wegovy and Mounjaro are injected the molecules are too large and active at too high a dose to deliver any other way (with the exception of Rybelsus, which uses sophisticated absorption enhancers to make oral semaglutide work)
Glucagon receptor activation adds energy expenditure and hepatic fat oxidation pathways not available with GLP-1 alone
Altered CAMKII expression, which regulates orexigenic neuropeptides like NPY, also reflected compensatory adaptation to weight loss (Sanchez-Garrido et al., 2024)
Microdosing GLP-1 vs